FAST - A prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Febuxostat (Primary) ; Allopurinol
Indications Gout
Focus Adverse reactions
Acronyms FAST

Most Recent Events

26 Jun 2023 Results (n=298 of BP sub-study) assessing The Effect of Allopurinol and Febuxostat on Blood Pressure in Adults with Chronic Hyperuricemia presented at the 32nd European meeting on hypertension and cardiovascular protection
10 Nov 2020 Results published in the Internet Document
05 Aug 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight